MHC-independent genetic factors control the magnitude of CD4 + T cell responses to amyloid-β peptide in mice through regulatory T cell-mediated inhibition

Journal of Immunology

Volumn 187, Issue 9, 2011, Pages 4492-4500

  Toly Ndour, Cécile ^a   Lui, Gabrielle ^a   Nunes, Maria Manuel ^a   Bruley Rosset, Martine ^a   Aucouturier, Pierre ^a   Dorothée, Guillaume ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[10-24]; AMYLOID BETA PROTEIN[16-30]; MAJOR HISTOCOMPATIBILITY ANTIGEN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; DOWN REGULATION; EPITOPE MAPPING; HAPLOTYPE; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOREGULATION; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; WILD TYPE;

ALLELES; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, INBRED DBA; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, REGULATORY;

EID: 80555133356     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003953     Document Type: Article

References (31)

1. Schenk, D., R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, et al. 1999. Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177. (Pubitemid 29327547)
2. Janus, C., J. Pearson, J. McLaurin, P. M. Mathews, Y. Jiang, S. D. Schmidt, M. A. Chishti, P. Horne, D. Heslin, J. French, et al. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982. (Pubitemid 32101644)
3. Morgan, D., D. M. Diamond, P. E. Gottschall, K. E. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D. Wilcock, et al. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985. (Pubitemid 32101645)
4. Nicoll, J. A., D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9: 448-452.
5. Ferrer, I., M. Boada Rovira, M. L. Sánchez Guerra, M. J. Rey, and F. Costa- Jussá. 2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14: 11-20. (Pubitemid 38200585)
6. Kellner, A., J. Matschke, C. Bernreuther, H. Moch, I. Ferrer, and M. Glatzel. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann. Neurol. 65: 24-31.
7. Cao, C., G. W. Arendash, A. Dickson, M. B. Mamcarz, X. Lin, and D. W. Ethell. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol. Dis. 34: 63-70.
8. Ethell, D. W., D. Shippy, C. Cao, J. R. Cracchiolo, M. Runfeldt, B. Blake, and G. W. Arendash. 2006. Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol. Dis. 23: 351-361. (Pubitemid 44097033)
9. Monsonego, A., V. Zota, A. Karni, J. I. Krieger, A. Bar-Or, G. Bitan, A. E. Budson, R. Sperling, D. J. Selkoe, and H. L. Weiner. 2003. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112: 415-422. (Pubitemid 38063770)
10. Zota, V., A. Nemirovsky, R. Baron, Y. Fisher, D. J. Selkoe, D. M. Altmann, H. L. Weiner, and A. Monsonego. 2009. HLA-DR alleles in amyloid betapeptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J. Immunol. 183: 3522-3530.
11. Monsonego, A., J. Imitola, S. Petrovic, V. Zota, A. Nemirovsky, R. Baron, Y. Fisher, T. Owens, and H. L. Weiner. 2006. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103: 5048-5053.
12. Radde, R., T. Bolmont, S. A. Kaeser, J. Coomaraswamy, D. Lindau, L. Stoltze, M. E. Calhoun, F. Jäggi, H. Wolburg, S. Gengler, et al. 2006. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7: 940-946. (Pubitemid 44523975)
13. Cribbs, D. H., A. Ghochikyan, V. Vasilevko, M. Tran, I. Petrushina, N. Sadzikava, D. Babikyan, P. Kesslak, T. Kieber-Emmons, C. W. Cotman, and M. G. Agadjanyan. 2003. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 15: 505-514. (Pubitemid 36432403)
14. Agadjanyan, M. G., A. Ghochikyan, I. Petrushina, V. Vasilevko, N. Movsesyan, M. Mkrtichyan, T. Saing, and D. H. Cribbs. 2005. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174: 1580-1586.
15. Kutzler, M. A., C. Cao, Y. Bai, H. Dong, P. Y. Choe, V. Saulino, L. McLaughlin, A. Whelan, A. Y. Choo, D. B. Weiner, and K. E. Ugen. 2006. Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine 24: 4630-4639. (Pubitemid 44218843)
16. Rosenkranz, D., S. Weyer, E. Tolosa, A. Gaenslen, D. Berg, T. Leyhe, T. Gasser, and L. Stoltze. 2007. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J. Neuroimmunol. 188: 117-127. (Pubitemid 47095016)
17. Hussain, S., S. J. Kirwin, and S. A. Stohlman. 2011. Increased T regulatory cells lead to development of Th2 immune response in male SJL mice. Autoimmunity 44: 219-228.
18. Chen, X., J. J. Oppenheim, and O. M. Howard. 2005. BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD252 responder T cells than C57BL/6 mice. J. Leukoc. Biol. 78: 114-121. (Pubitemid 40979950)
19. Bassuny, W. M., K. Ihara, Y. Sasaki, R. Kuromaru, H. Kohno, N. Matsuura, and T. Hara. 2003. A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes. Immunogenetics 55: 149-156. (Pubitemid 36819361)
20. Lin, Y. C., J. H. Lee, A. S. Wu, C. Y. Tsai, H. H. Yu, L. C. Wang, Y. H. Yang, and B. L. Chiang. 2011. Association of single-nucleotide polymorphisms in FOXP3 gene with systemic lupus erythematosus susceptibility: a case-control study. Lupus 20: 137-143.
21. Gao, L., K. Li, F. Li, H. Li, L. Liu, L. Wang, Z. Zhang, T. Gao, and Y. Liu. 2010. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J. Dermatol. Sci. 57: 51-56.
22. Ban, Y., T. Tozaki, T. Tobe, Y. Ban, E. M. Jacobson, E. S. Concepcion, and Y. Tomer. 2007. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: an association analysis in Caucasian and Japanese cohorts. J. Autoimmun. 28: 201-207. (Pubitemid 46805032)
23. Park, O., I. Grishina, P. S. Leung, M. E. Gershwin, and T. Prindiville. 2005. Analysis of the Foxp3/scurfin gene in Crohn's disease. Ann. N. Y. Acad. Sci. 1051: 218-228. (Pubitemid 41362750)
24. Pfeifer, M., S. Boncristiano, L. Bondolfi, A. Stalder, T. Deller, M. Staufenbiel, P. M. Mathews, and M. Jucker. 2002. Cerebral hemorrhage after passive anti- Abeta immunotherapy. Science 298: 1379. (Pubitemid 35346131)
25. Thakker, D. R., M. R. Weatherspoon, J. Harrison, T. E. Keene, D. S. Lane, W. F. Kaemmerer, G. R. Stewart, and L. L. Shafer. 2009. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc. Natl. Acad. Sci. USA 106: 4501-4506.
26. Salloway, S., R. Sperling, S. Gilman, N. C. Fox, K. Blennow, M. Raskind, M. Sabbagh, L. S. Honig, R. Doody, C. H. van Dyck, et al. Bapineuzumab 201 Clinical Trial Investigators. 2009. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070.
27. Holmes, C., D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, A. Bayer, R. W. Jones, R. Bullock, S. Love, J. W. Neal, et al. 2008. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223. (Pubitemid 351978111)
28. Schwartz, M., and R. Shechter. 2010. Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol. 6: 405-410.
29. Butovsky, O., M. Koronyo-Hamaoui, G. Kunis, E. Ophir, G. Landa, H. Cohen, and M. Schwartz. 2006. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. USA 103: 11784-11789. (Pubitemid 44182528)
30. Fisher, Y., A. Nemirovsky, R. Baron, and A. Monsonego. 2010. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS ONE 5: e10830.
31. Kipnis, J., H. Avidan, R. R. Caspi, and M. Schwartz. 2004. Dual effect of CD4+ CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia. Proc. Natl. Acad. Sci. USA 101(Suppl. 2): 14663-14669. (Pubitemid 39346740)